Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt

Kidney International

Volumn 75, Issue 9, 2009, Pages 936-944

  Lea, William B ^a   Kwak, Eun Soo ^a   Luther, James M ^a   Fowler, Susan M ^a   Wang, Zuofei ^a   Ma, Ji ^a   Fogo, Agnes B ^a   Brown, Nancy J ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aldosterone; Mineralocorticoid receptor; Plasminogen activator inhibitor 1

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN II; CORTICOSTERONE; FAD 286; MESSENGER RNA; OSTEOPONTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SPIRONOLACTONE; SYNTHETASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ALBUMINURIA; ALDOSTERONE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; GLOMERULOPATHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY HYPERTROPHY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE; UNINEPHRECTOMY; UREMIA;

ALDOSTERONE ANTAGONISTS; ALDOSTERONE SYNTHASE; ANGIOTENSIN II; ANIMALS; ENZYME INHIBITORS; FIBROSIS; HEART DISEASES; KIDNEY DISEASES; RATS; RECEPTORS, MINERALOCORTICOID; SODIUM CHLORIDE, DIETARY; SPIRONOLACTONE;

EID: 64949189157     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.9     Document Type: Article

References (37)

1. Brilla CG, Matsubara LS, Weber KT Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism J Mol Cell Cardiol 1993; 25 563-575.
2. Young M, Fullerton M, Dilley R et al Mineralocorticoids, hypertension, and cardiac fibrosis J Clin Invest 1994; 93 2578-2583.
3. Greene EL, Kren S, Hostetter TH Role of aldosterone in the remnant kidney model in the rat J Clin Invest 1996; 98 1063-1068.
4. Benetos A, Lacolley P, Safar ME Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats Arterioscler Thromb Vasc Biol 1997; 17 1152-1156.
5. Rocha R, Rudolph AE, Frierdich GE et al Aldosterone induces a vascular inflammatory phenotype in the rat heart Am J Physiol Heart Circ Physiol 2002; 283 H1802-H1810.
6. Blasi ER, Rocha R, Rudolph AE et al Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats Kidney Int 2003; 63 1791-1800.
7. Rocha R, Chander PN, Khanna K et al Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats Hypertension 1998; 31 451-458.
8. Fiebeler A, Schmidt F, Muller DN et al Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury Hypertension 2007; 37 787-793.
9. Young M, Funder JW Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats Endocrinology 2004; 145 3153-3157.
10. Neves MF, Amiri F, Virdis A et al Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy Can J Physiol Pharmacol 2005; 83 999-1006.
11. Struthers AD. Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J 1995; 16(Suppl N): 103-106.
12. Pitt B, Zannad F, Remme WJ et al The effect of spironolactone on morbidity and mortality in patients with severe heart failure N Engl J Med 1999; 341 709-717.
13. Zannad F, Alla F, Dousset B et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES) Rales Investigators Circulation 2000; 102 2700-2706.
14. Sato A, Hayashi K, Saruta T Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease Am J Hypertens 2005; 18 44-49.
15. Mihailidou AS, Mardini M, Funder JW Rapid, nongenomic effects of aldosterone in the heart mediated by epsilon protein kinase C Endocrinology 2004; 145 773-780.
16. Jaffe IZ, Mendelsohn ME Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells Circ Res 2005; 96 643-650.
17. Wehling M, Neylon CB, Fullerton M et al Nongenomic effects of aldosterone on intracellular Ca2+ in vascular smooth muscle cells Circ Res 1995; 76 973-979.
18. Schneider M, Ulsenheimer A, Christ M et al Nongenomic effects of aldosterone on intracellular calcium in porcine endothelial cells Am J Physiol 1997; 272 E616-E620.
19. Alzamora R, Marusic ET, Gonzalez M et al Nongenomic effect of aldosterone on Na+,K+-adenosine triphosphatase in arterial vessels Endocrinology 2003; 144 1266-1272.
20. Fiebeler A, Nussberger J, Shagdarsuren E et al Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage Circulation 2005; 111 3087-3094.
21. Rocha R, Martin-Berger CL, Yang P et al Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart Endocrinology 2002; 143 4828-4836.
22. Minnaard-Huiban M, Emmen JM, Roumen L et al Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats: discordant enantioselectivity versus reduction of plasma aldosterone Endocrinology 2008; 149 28-31.
23. Quaschning T, Ruschitzka F, Shaw S et al Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension Hypertension 2001; 37 801-805.
24. Okada T, Nagai M, Taniguchi I et al Combined treatment with valsartan and spironolactone prevents cardiovascular remodeling in renovascular hypertensive rats Int Heart J 2006; 47 783-793.
25. Karim A, Kook C, Zitzewitz DJ et al Species differences in the metabolism and disposition of spironolactone Drug Metab Dispos 1976; 4 547-555.
26. Chai W, Garrelds IM, de Vries R et al Nongenomic effects of aldosterone in the human heart: interaction with angiotensin II Hypertension 2005; 46 701-706.
27. Nicoletti A, Heudes D, Hinglais N et al. Left ventricular fibrosis in renovascular hypertensive rats Effect of losartan and spironolactone Hypertension 1995; 26 101-111.
28. Rossier MF, Lesouhaitier O, Perrier E et al Aldosterone regulation of T-type calcium channels J Steroid Biochem Mol Biol 2003; 85 383-388.
29. Mironneau J Calcium channel antagonist effects of spironolactone, an aldosterone antagonist Am J Cardiol 1990; 65 7K-8K.
30. Brown NJ, Nakamura S, Ma L-J et al Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo Kidney Int 2000; 58 1219-1227.
31. Fujisawa G, Okada K, Muto S et al Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats Kidney Int 2004; 66 1493-1502.
32. Ma J, Weisberg A, Griffin JP et al Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury Kidney Int 2006; 69 1064-1072.
33. Oestreicher EM, Martinez-Vasquez D, Stone JR et al Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury Circulation 2003; 108 2517-2523.
34. Mazak I, Fiebeler A, Muller DN et al Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells Circulation 2004; 109 2792-2800.
35. Brown NJ, Nakamura S, Ma L et al Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo Kidney Int 2000; 58 1219-1227.
36. Brown NJ, Bradford J, Wang Z et al Modulation of angiotensin II and norepinephrine-induced plasminogen activator inhibitor-1 expression by AT1a receptor deficiency Kidney Int 2007; 72 72-81.
37. Naftilan AJ, Pratt RE, Eldridge CS et al Angiotensin II induces c-fos expression in smooth muscle via transcriptional control Hypertension 1989; 13 706-711.